InflaRx

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees74

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees74

IFRX Key Statistics

Market cap

53.87M

Market cap53.87M

Price-Earnings ratio

-0.77

Price-Earnings ratio-0.77

Dividend yield

—

Dividend yield—

Average volume

1.24M

Average volume1.24M

High today

$0.82

High today$0.82

Low today

$0.7702

Low today$0.7702

Open price

$0.8025

Open price$0.8025

Volume

437.46K

Volume437.46K

52 Week high

$2.82

52 Week high$2.82

52 Week low

$0.7113

52 Week low$0.7113

IFRX News

Seeking Alpha 5d

InflaRx plunges on plans to halt studies into lead asset in rare skin disorder

InflaRx (NASDAQ:IFRX) lost over half of its market cap in the premarket on Wednesday after the German biotech announced it would discontinue studies into its le...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.